Loratadine

Samantha Avivi appointed as new Chief Marketing Officer of Consumer Health, North America division. Current CMO Jeff Jarrett to retire after five years with Bayer. WHIPPANY, N.J.--(BUSINESS WIRE)-- Today, Bayer announced Samantha Avivi as the new Chief Marketing Officer (CMO) for its Consumer Health division in North America. She will report directly to Dave Tomasi, President, Consumer Health, North America for Bayer. Avivi will succeed Jeff Jarrett, who is retiring from the company at the end of May. This press release features multimedia. View the full release here: Samantha Avivi (Photo: Business Wire) “I’m pleased to welcome Samantha to Team Bayer to lead our North America marketing organization and join our efforts to achieve ‘Health for all, Hunger for none,‘” said Tomasi. “She has expertise in setting groundbreaking visions, igniting breakthrough growth, accelerating multifunctional teams, with a proven track record of growing businesses, brands and most importantly, people.” “I also want to sincerely thank Jeff Jarrett for his dedication to the company, to our mission, and to our people,” continued Tomasi. “He’s been a driver of innovation, a champion of marketing excellence, a key leader in advancing the turnaround of our Consumer Health business, and a huge advocate for Diversity, Equity & Inclusion at Bayer. While he is leaving Bayer, the friendships he’s forged here will continue, and I wish him all the best in this exciting next chapter.” Samantha has over 25 years of client, retail and agency experience at some of the world’s largest companies like P&G, Kimberly Clark, Walmart, BBDO and Y&R. She was most recently the Chief Marketing Officer at Advance Auto Parts where she owned and executed the company’s omnichannel strategy and operations including a comprehensive marketing vision, philosophy, and plan. During her tenure, she inspired forward-looking programs in support of Advance Auto Parts and its portfolio of brands. “I’m honored to take this leadership role with Bayer, a world leading company with a meaningful mission,” said Avivi. “I’m excited to leverage my passion for building consumer-led, purpose-driven brands across the Consumer Health portfolio, which includes many brands that I know and love, like Claritin, Aspirin, and Midol.” Prior to Advance Auto Parts, Samantha was the CMO at Tenneco, where she led a portfolio of 31 brands across 42 product lines in 26 countries. Samantha is a graduate of the University of Florida with a Bachelor of Business Administration (BBA). About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to bayer.com.

Study identifies persistent Lyme bacteria in tissue samples and points to need for clinical studies of combination antibiotics in persistent LymePORTOLA VALLEY, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation, a leading public foundation sponsor of Lyme disease research in the US, today announced results of a laboratory study published in the peer-reviewed journal Frontiers in Microbiology that identifies seven combination therapies that are superior to courses of single antibiotics for treating persistent Lyme disease in an investigational model. These combination therapies were able to eradicate the bacteria from tissue samples, and the study was conducted by Bay Area Lyme Foundation Scientific Advisory Board member Monica Embers Ph.D., along with other researchers from Tulane University. “Our results support the experience of Lyme disease patients whose symptoms have not resolved after a standard course of antibiotics, and these new data suggest that combination therapy should be investigated in clinical studies for treating persistent human Lyme disease,” said Embers, an associate professor of microbiology and immunology and director of Vector-borne Disease Research at Tulane National Primate Research Center. While none of the single courses of antibiotics eliminated persistent infection in this investigational study, some combinations of already FDA-approved antimicrobial treatments were able to eradicate the bacteria. Specifically, four different dual combinations of antibiotics (doxycycline and ceftriaxone; dapsone and rifampicin; dapsone and clofazimine; doxycycline and cefotaxime) and three triple combinations of antibiotics and antimicrobials (doxycycline, ceftriaxone and carbomycin; doxycycline, cefotaxime and loratadine; dapsone, rifampicin and clofazimine) eradicated persistent infections of Borrelia burgdorferi, the bacteria that causes Lyme disease. “With no FDA-approved treatment for persistent Lyme, these data will bring much-needed hope to the approximately 2 million Americans who live with symptoms such as chronic pain, fatigue, and cognitive dysfunction due to this terrible disease,” said Linda Giampa, executive director of the Bay Area Lyme Foundation. “Importantly, this is yet another study demonstrating the existence of persistent infection following a standard course of antibiotics.” In this study, Borrelia burgdorferi was found in tissue cultures taken after a 28-day course of a single antibiotic treatment, supporting previous data showing that the bacteria can persist following standard treatment. Conversely, viable Borrelia burgdorferi was not detected in cultured tissues following administration of the seven treatment combinations. Previous studies funded by Bay Area Lyme Foundation also found other compounds, including natural botanicals, to show promise in killing Borrelia burgdorferi and superiority over commonly prescribed antibiotics in laboratory research. This study was made possible by Bay Area Lyme Foundation’s science research grant program, which includes support from Project Lyme. About Lyme disease The most common vector-borne infectious disease in the US, Lyme disease is a potentially disabling infection caused by bacteria transmitted through the bite of an infected tick to people and pets, and can be potentially passed from a pregnant mother to her unborn baby. If caught early, most cases of Lyme disease can be effectively treated, but it is commonly misdiagnosed due to lack of awareness and inaccurate diagnostic tests. There are almost 500,000 new cases of Lyme disease each year, according to statistics released in 2018 by the CDC. As a result of the difficulty in diagnosing and treating Lyme disease, up to two million Americans may be suffering from the impact of its debilitating long-term symptoms and complications, according to Bay Area Lyme Foundation estimates. About Bay Area Lyme Foundation Bay Area Lyme Foundation, a national organization committed to making Lyme disease easy to diagnose and simple to cure, is the leading public not-for-profit sponsor of innovative Lyme disease research in the US. A 501c3 organization based in Silicon Valley, Bay Area Lyme Foundation collaborates with world-class scientists and institutions to accelerate medical breakthroughs for Lyme disease. It is also dedicated to providing reliable, fact-based information so that prevention and the importance of early treatment are common knowledge. A pivotal donation from The LaureL STEM FUND covers overhead costs and allows for 100% of all donor contributions to the Bay Area Lyme Foundation to go directly to research and prevention programs. For more information about Lyme disease or to get involved, visit www.bayarealyme.org or call us at 650-530-2439. Media contact: Tara DiMilia Phone: 908-369-7168 Tara.DiMilia@tmstrat.com